Milestone Pharmaceuticals Inc (MIST) - Long-Term Liabilities to Capital

Symbol and logo of brand Milestone Pharmaceuticals (MIST)

Milestone Pharmaceuticals (MIST) research hubs in North America are developing medications to combat cardiac pathologies, leveraging their own patents for arrhythmia therapy. The business operates within an autonomous cycle, rendering it resilient to market volatility and a reliable defensive asset. The price action history, where the indicator stands at 7.14, underscores the company's dependence on FDA certification for its nasal tachycardia treatment.

Milestone Pharmaceuticals, Inc. (MIST): Long-Term Debt to Equity from 07/04/2022 to 10/29/2026

Analytical breakdowns for Milestone Pharmaceuticals

- share price and expert price forecast:
Price Performance Chart Milestone Pharmaceuticals, Inc.|MIST - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Milestone Pharmaceuticals Inc.|MIST - Enterprise Value
- book value of equity indicators:
Book Value per Share Milestone Pharmaceuticals|MIST - Company Book Value|Market Value to Book Value milestonepharma.com|MIST - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Milestone Pharmaceuticals|MIST - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio milestonepharma.com|MIST - Company Aggregate Debts|Debts to Net Assets Milestone Pharmaceuticals Inc.|MIST - Company Long-Term Debt|Company Short-Term Debt Milestone Pharmaceuticals|Immediate Liquidity milestonepharma.com
- net income and valuation ratios data:
MIST - Company Net Income
Summary company analysis:Milestone Pharmaceuticals
Finished products of Milestone Pharmaceuticals Inc.

For Milestone Pharmaceuticals (MIST), which protects its innovative etripamil nasal spray with patents, the long-term debt-to-equity trend reflects a balance between funding expansion and maintaining financial autonomy. This metric relates liabilities with a maturity of over one year to shareholders' equity, allowing investors to assess the degree of leverage and the risk of default in the absence of operating profit.

Analysis of competing companies

REGN: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital IRTC|LNTH - Long-Term Liabilities to Capital|Long-Term Debt to Capital MLYS (Mineralys Therapeutics)|Long-Term Debt to Capital HeartFlow Medical HTFL|KMTS - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient ESPR (Esperion Therapeutics, Inc.)|AMRN (Amarin Corp) - Long-Term Debt to Equity Ratio|AVR: Long-Term Loans to Capital Ratio|Long-Term Debt to Equity Tenaya|Long-Term Debt to Equity Ratio cvrx.com (CVRX)|Long-Term Debt to Capital CRDL|Ratio of Long-Term Indebtedness to Capital HeartBeam Inc|Long-Term Debt to Equity Tenax Therapeutics, Inc TENX|Adagio Medical, Inc. - Long-Term Debt to Equity|BioCardia, Inc. - Long-Term Debt to Capital|Long-Term Liabilities to Capital catheterprecision.com|arcabio.com (ABIO) - Long-Term Debt to Equity|ACST - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio AVTE|VERV (Verve) - Long-Term Loans to Capital Ratio|Long-Term Debt to Equity Windtree Therapeutics (WINT)